Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2001

View Archived Issues

First nonpeptide somatotropin sst3 antagonists reported

Genzyme acquires Novazyme Pharmaceuticals

Enrollment completed in second phase III trial of ranolazine for chronic angina

Phase I results reported for Merck KGaA's anti-EGF receptor MAb

Patient enrollment for phase I study of RIGScan CR set to begin

Colon cancer proteomics discovery partnership signed by Genomics Collaborative and ActivX

EMEA awards orphan product status to Surfaxin for MAS

Desloratadine approved in the E.U. for symptoms of chronic idiopathic urticaria

Strategy for systemic administration of Reolysin explored

Merck & Co. reports novel farnesyltransferase inhibitor with excellent cell potency

Compounds useful as cell adhesion inhibitors patented by Aventis and Genentech

Taisho identifies PGD2-like agonists potentially useful for cardiovascular disorders

PG derivatives for prevention and treatment of vascular hypertrophy described by Taisho

NK1 antagonists useful for treating asthma and allergic rhinitis reported by UCB

COR Therapeutics reports new selective factor Xa inhibitors

Quadruple therapy including both nelfinavir and efavirenz improves response in HIV patients

Copaxone approved by 15 European countries for the treatment of MS

Transtec receives marketing approval in Germany for the treatment of nonacute pain

FDA advisory committee recommends approval of Tracleer for PAH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...